Physician profile
Ryan R Rees
NPI 1558361428
$2,607.92
in general payments reported to CMS, 2019-2025
29 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $123 · 2021: $93.41 · 2022: $443 · 2023: $777 · 2024: $511 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $306.18 | 2021-2025 | |
| Pfizer INC. | $291.98 | 2022-2025 | |
| Abbott Laboratories | $234.57 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $227.01 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $167.88 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $107.60 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $99.60 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $81.62 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $75.00 | 2019-2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $69.15 | 2020-2025 | Otezla, Repatha, Repatha |
| Renalytix Ai, INC. | $61.76 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $55.14 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $49.96 | 2020 | |
| Xeris Pharmaceuticals, INC. | $40.98 | 2023 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.82 | 2019-2021 | |
| Dynavax Technologies Corporation | $29.44 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $28.17 | 2023 | Quviviq |
| Medtronic, INC. | $24.36 | 2025 | Minimed 780g |
| Noven Therapeutics, LLC | $23.08 | 2025 | Xelstrym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2019 | |
| Sanofi Pasteur INC. | $17.44 | 2019 | |
| Sumitomo Pharma America, INC. | $17.36 | 2023 | Gemtesa |
| Allergan, INC. | $16.97 | 2019 | |
| Amarin Pharma, INC. | $16.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.93 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $15.69 | 2022 | |
| Nabriva Therapeutics, Plc | $12.93 | 2020 | |
| Ethicon US, LLC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.